Articles tagged with Ovarian Cancer
Researchers identified four novel receptors potentially linking endometrial cancer with polycystic ovary syndrome, highlighting a major pathway involved in the increased EC risk in PCOS. The PI3K-AKT signaling pathway is consistent with a link between PCOS and EC.
A new nuclear medicine treatment has been shown to cure a highly lethal form of advanced intraperitoneal ovarian cancer in a preclinical setting. The therapy targets the HER2 protein and achieved high potency while maintaining an acceptable safety profile.
Researchers found a strong positive correlation between BRD4 overexpression and chemoresistance in ovarian cancer. The study demonstrated that BRD4-L and BRD4-S isoforms play a role in promoting chemotherapy resistance in high-grade serous ovarian carcinoma.
A team of Chinese and UK researchers has identified superoxide dismutase 1 (SOD1) as a potential target for reversing drug resistance in ovarian cancer. By using nanoparticles to deliver siRNA that reduces SOD1 levels, the study showed reduced growth and decreased resistance to cisplatin in female mice.
A Swedish study revealed that including all eleven associated genes in the screening test doubled the proportion of women with genetically confirmed hereditary breast cancer. The study included 4759 individuals and found that around 85% of women investigated for suspected hereditary breast cancer had a genetic abnormality.
Researchers successfully deployed CAR-T therapy in a mouse model of ovarian cancer, demonstrating strong anti-tumor effects even at late stages. The treatment was highly effective, shrinking or eliminating tumors after just one dose and continuing to work for months without major side effects.
Researchers have discovered a 64-protein signature that can predict which ovarian cancer patients are unlikely to respond to chemotherapy, paving the way for personalized treatment options. The study also identifies five new subtypes of high-grade serous ovarian cancer, suggesting different treatment strategies may be needed.
A secondary analysis of a randomized clinical trial found that exercise can significantly reduce symptoms of chemotherapy-induced peripheral neuropathy (CIPN) in ovarian cancer survivors. Incorporating exercise programs into standard oncology care may improve quality of life for these patients.
Researchers discovered that obesity affects ovarian cancer by altering the tumor's immune microenvironment and stiffening surrounding tissue. This change impairs treatment response to chemotherapy, leading to poorer survival rates among patients with high body mass index (BMI).
A new study reveals that cancer cells reprogram normal mesothelial cells into cancer-associated mesothelial cells through the AMH axis, promoting tumor growth and immune evasion. Disrupting this signal slows tumor growth and helps the immune system overcome some of its defenses.
A synoptic report improved the completeness of pretreatment CT reports in patients with advanced ovarian cancer. Involvement of surgically established unresectable or challenging-to-resect disease sites was mentioned in all disease-specific synoptic reports, compared to 37% of simple structured reports.
A case-control study found associations between certain jobs and increased risks of ovarian cancer. Hairdressers, beauticians, and accountants were linked to higher risks, with cumulative exposure to agents like talcum powder and ammonia also contributing.
Researchers at Nagoya University have discovered three new biomarkers for high-grade serous ovarian carcinoma using membrane proteins and polyketone-coated nanowires. The study reveals that small extracellular vesicles containing these proteins can be used to detect ovarian cancer, potentially leading to personalized medicine.
Researchers have developed a new technique to generically treat several kinds of cancer, showing tumors grew almost three times less and survival rates reached 100% after just one injection. The method targets cancer cells with alpha radiation, sparing healthy tissue.
A nationwide study of nearly two million women found that those with PCOS who have undergone menopause are more than twice as likely to be diagnosed with ovarian cancer. The risk was also significantly higher for a type of ovarian tumor known as serous borderline, which can lead to cancer later on.
Researchers at Imperial College London have found that tumors with tertiary lymphoid structures (TLS) in high-grade ovarian cancer respond better to treatment. Genes like IL15 and CXCL10 play a role in TLS formation, while DCAF15 interacts with these tissues. An AI algorithm can detect TLS on CT scans, enabling early identification of ...
A new study reveals that the protein complex BCDX2 plays a critical role in DNA repair, suggesting mutations in this complex could lead to cancer. The research also highlights the importance of screening for mutations in people with a family history of breast and ovarian cancers.
Researchers found that only 6.8% of cancer patients underwent genetic testing within two years of diagnosis, with lower rates among Black, Hispanic, and Asian patients. The low rates are attributed to lack of integration of test results into cancer management and prevention.
A phase I study found significant clinical benefit of the ADC luveltamab tazevibulin in patients with recurrent ovarian cancer expressing high levels of folate receptor alpha, with an overall response rate of 37.5% and a 44% response rate at higher doses.
A UTHSC research collaboration has been awarded a national grant to develop a new treatment for ovarian cancer. The project will test a newer generation of sabizabulin, a clinical candidate targeting microtubules in cancer cells.
Researchers discuss chemotherapeutic resistance in recurring ovarian cancer, focusing on the unfolded protein response and its effect on polyploid giant cancer cells. Understanding this mechanism could lead to investigating cancer cell molecular mechanisms and potential therapeutic strategies.
The PARIS Test, a CLIA-certified drug sensitivity assay, uses patient-derived tumor organoids to screen an array of drugs and develop personalized treatment reports. Ibrutinib, a BTK inhibitor approved only for certain leukemias and lymphomas, was identified as the optimal treatment for a patient with ovarian cancer.
Researchers have identified three subtypes of ovarian high-grade serous carcinoma (HGSC) based on genomic changes, which may help tailor therapies. The study's findings could improve treatment outcomes for patients with this aggressive subtype.
Overweight and obesity in early adulthood are associated with increased risks of colorectal cancer and non-colorectal gastrointestinal cancers. The study highlights the need for further exploration into the mechanisms driving these associations.
A new study finds that one-time genomic screening of adults aged 20-60 for hereditary breast and ovarian cancer syndrome, Lynch syndrome, and familial hypercholesterolemia is cost-effective based on quality-adjusted life-year measures. The study suggests that this approach could improve disease management and reduce healthcare costs.
A recent Fred Hutchinson Cancer Center study found that fibroids were associated with an increased risk of ovarian cancer in both Black and white women, while hysterectomy modified this risk for white women but not Black women. The study highlights the need for further research into racial disparities in ovarian cancer risk.
A new study suggests combining digital cancer risk assessment with point-of-care genetic testing can help overcome clinical workflow challenges that prevent at-risk patients from accessing genetic testing. The approach more than doubled the average uptake of genetic testing, showing promise for cancer prevention and detection.
Researchers found that removing ovaries during a benign hysterectomy increases the risk of hospitalization for cardiovascular disease in premenopausal women, but not necessarily for cancer. The study supports current recommendations to conserve ovaries in premenopausal patients at low risk for ovarian cancer.
Researchers have reported promising results in rare gynecologic cancers from the DART immunotherapy trial, with durable responses and complete remissions observed in patients. The findings suggest a potential new treatment approach for these previously underserved patient populations.
A new target for drug-resistant ovarian cancer has been identified through a preclinical study led by researchers at Penn Medicine. An antibody-drug conjugate targeting B7-H4 showed significant anti-tumor activity and sustained response in treatment-resistant models.
A new study reveals the mechanism of BRCA2's DNA repair function, understanding its role in breast and ovarian cancer development. The findings also provide insights into developing targeted cancer therapies by inhibiting DNA repair mechanisms.
A phase II trial investigating the combination of ribociclib and letrozole showed a response rate of 23%, progression-free survival of 19.1 months, and duration of response of 19.1 months in patients with recurrent low-grade serous ovarian cancer.
Researchers at the Mayo Clinic found that surgical removal of both ovaries in women under 43 increases their risk of developing Parkinson's disease and parkinsonism. The study used health record data from the Rochester Epidemiology Project to analyze over 2,750 women who underwent bilateral oophorectomy.
Researchers from Swansea University and Université Grenoble Alpes demonstrate the effectiveness of selenium nanoparticles in killing ovarian cancer cell models. The study reveals a novel biological mechanism underlying the anti-cancer effect, involving histone methylatransferases and epigenetic processes.
Researchers discovered that quiescent ovarian cancer cells secrete follistatin, which induces resistance in neighboring cells and worsens survival rates. Targeting this protein may improve chemotherapy response and boost survival in patients with aggressive ovarian cancer.
A new study found that women with BRCA1 or BRCA2 mutations have a cumulative risk of 49% developing any type of cancer after age 50. Risk-reducing surgeries like mastectomies and BSOs can lower this risk, but many women opt out despite elevated risk. Genetic testing is crucial for accurate risk assessment and personalized care.
The ESMO Gynaecological Cancers Congress 2023 will present the latest treatments and insights for ovarian, uterine, cervical, and rare gynaecological cancers. Around 80 studies will be presented on strategies to overcome PARP inhibitors mechanisms of resistance in ovarian cancer.
Researchers at Karolinska Institutet have developed a new type of CAR T-cell therapy that effectively attacks and destroys ovarian cancer cells, significantly prolonging the lives of mice with the disease. The treatment has shown promising results in reducing tumor size and curing several mice.
A new study suggests that higher consumption of ultra-processed foods may be linked to an increased risk of developing and dying from cancer. The study found that each 10% increase in ultra-processed food consumption was associated with a 2% increase in cancer incidence, as well as a 6% increase in mortality from cancer.
A study suggests that loyalty card data on over-the-counter medicine purchases could help spot ovarian cancer cases earlier. Women with ovarian cancer were found to buy more pain and indigestion medications before diagnosis, often up to 8 months prior. This could lead to improved survival rates if symptoms are picked up earlier.
A study found a link between pain and indigestion medication purchases and ovarian cancer diagnoses, suggesting earlier symptom recognition. The research suggests that loyalty card data can be used to identify potential ovarian cancer cases.
A new study suggests that acupressure before surgery can reduce anxiety, while acupuncture during surgery may provide additional relief from severe pain. The research found that patients who received these treatments had better recovery scores and lower levels of pain and anxiety compared to those who received standard care.
A study by Mayo Clinic researchers found a specific colonization of microbes in the reproductive tract is commonly found in women with ovarian cancer. The discovery strengthens evidence that the bacterial component of the microbiome is an important indicator for early detection, diagnosis, and prognosis of ovarian cancer.
A new genetic test has been developed to identify ovarian cancer patients who benefit from PARP inhibitors, a treatment option with significant improvements in prognosis. The test has been optimized for the Finnish population and is clinically approved, allowing for targeted treatment and reduced adverse effects.
A new software developed by researchers at Cold Spring Harbor Laboratory can accurately infers continental ancestry from tumor DNA and RNA. This technology has the potential to lead to more targeted and personalized cancer treatments by identifying genetic connections between cancer and race or ethnicity.
Researchers at Memorial Sloan Kettering Cancer Center have discovered several mechanisms of immune escape that contribute to ovarian cancer's resistance to immunotherapy. The study reveals that ovarian tumors develop new mutations to evade the immune system as they spread, making it challenging to identify a marker for predicting respo...
The National Cancer Institute awards $10.5 million to USC's Division of Biostatistics to develop statistical methods for uncovering new risk factors associated with cancer by integrating large volumes of health, genomic, and exposure data. The project aims to provide new insights into complex biological processes and discoveries of nov...
Researchers analyzed genetic data from 233 patients with ovarian cancer and found that precise localization of BRCA gene mutations is crucial for effective treatment. The study suggests that PARP inhibitors can be highly effective in patients with mutations in the DNA-binding domain, leading to improved overall survival rates.
The ESMO Asia Congress 2022 will focus on the latest scientific and clinical advances in oncology, with a special emphasis on the Asia-Pacific region. Media representatives can register for coverage through the official media registration form.
In a recent study, researchers targeted the POL theta enzyme to inhibit DNA production in cancer cells. The approach represents a new method for developing specific therapies for patients with BRCA1 mutations.
A study of 11,945 people found that those with type 2 diabetes are more likely to be diagnosed with advanced cancer if the condition is not screened for routinely. Researchers identified a 26% increased risk of metastasis in patients with pre-existing type 2 diabetes.
A new study found that BRCA1/2 mutation-associated cancers have specific features that contribute to their high risk of recurrence, including changes in the BRCA2 protein's messenger-RNA molecule. The researchers identified multiple novel markers of therapeutic resistance, highlighting the importance of tumor profiling at treatment time.
A new study published in JNCCN found significant disparities in ovarian cancer treatment based on patient race, ability to pay, and healthcare access. Non-Hispanic Black patients were less likely to receive guideline-appropriate treatment compared to White patients.
Research suggests that antibiotics used in ovarian cancer treatment can accelerate cancer progression and lower survival rates. Reintroducing healthy gut bacteria may slow down cancer growth and restore sensitivity to chemotherapy.
Two new discoveries led by Cedars-Sinai Cancer investigators improve understanding of ovarian cancer's development and suggest personalized therapeutic approaches. They identified four new genetic regions linked to increased ovarian cancer risk and found that some tumors may develop resistance to chemotherapy from an early stage.
A specialized triage algorithm, ROCA test, enables earlier stage diagnosis in women deferring preventive surgery, saving NHS costs. The approach results in fewer major surgical interventions and lower risk of wider disease spread.
A Phase Ib clinical trial found that sequential administration of PARP inhibitor olaparib and WEE1 inhibitor adavosertib is safe and well-tolerated, with promising signs of anti-tumor activity in patients with advanced cancers driven by DNA damage response mutations. The combination showed durable responses in patients with resistant c...
Researchers have found a drug that targets the key, cancer-causing gene MYC has been able to inhibit its function safely and effectively. Eight out of 12 patients showed stabilisation of disease after treatment with OMO-103, with one patient experiencing a reduction in tumour-derived DNA circulating in the blood stream.
A meta-analysis of 410 articles from 68 countries found that patients in lower-income countries take up to four times longer to initiate care for cancer treatment. Cancers causing non-specific symptoms, such as myeloma and colorectal cancer, typically take the longest to diagnose.
A new potential antitumor drug, TRIP, causes rapid protein aggregation, hyperactivating the unfolded protein response and leading to programmed cell death in ovarian cancer cells. The Fe-S cluster biogenesis factor NUBP2 is identified as the probable starting point for the cellular processes triggered by TRIP.